PL2215075T3 - Pochodne chinolinonu jako inhibitory PARP - Google Patents

Pochodne chinolinonu jako inhibitory PARP

Info

Publication number
PL2215075T3
PL2215075T3 PL08841176T PL08841176T PL2215075T3 PL 2215075 T3 PL2215075 T3 PL 2215075T3 PL 08841176 T PL08841176 T PL 08841176T PL 08841176 T PL08841176 T PL 08841176T PL 2215075 T3 PL2215075 T3 PL 2215075T3
Authority
PL
Poland
Prior art keywords
parp inhibitors
quinolinone derivatives
quinolinone
derivatives
parp
Prior art date
Application number
PL08841176T
Other languages
English (en)
Polish (pl)
Inventor
Patrick René Angibaud
Laurence Françoise Bernadette Marconnet-Decrane
Jorge Eduardo Vialard
Laurence Anne Mevellec
Christophe Meyer
Pierre-Henri Storck
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of PL2215075T3 publication Critical patent/PL2215075T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
PL08841176T 2007-10-26 2008-10-22 Pochodne chinolinonu jako inhibitory PARP PL2215075T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP07119417 2007-10-26
PCT/EP2008/064243 WO2009053373A1 (en) 2007-10-26 2008-10-22 Quinolinone derivatives as parp inhibitors
EP08841176.4A EP2215075B1 (en) 2007-10-26 2008-10-22 Quinolinone derivatives as parp inhibitors

Publications (1)

Publication Number Publication Date
PL2215075T3 true PL2215075T3 (pl) 2014-04-30

Family

ID=39345428

Family Applications (1)

Application Number Title Priority Date Filing Date
PL08841176T PL2215075T3 (pl) 2007-10-26 2008-10-22 Pochodne chinolinonu jako inhibitory PARP

Country Status (6)

Country Link
US (1) US8404713B2 (enExample)
EP (1) EP2215075B1 (enExample)
JP (1) JP5525447B2 (enExample)
ES (1) ES2448870T3 (enExample)
PL (1) PL2215075T3 (enExample)
WO (1) WO2009053373A1 (enExample)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8889730B2 (en) 2012-04-10 2014-11-18 Pfizer Inc. Indole and indazole compounds that activate AMPK
JP6345651B2 (ja) * 2012-05-09 2018-06-20 サノビオン ファーマシューティカルズ インクＳｕｎｏｖｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃ． ヘテロアリール化合物及びその使用方法
WO2014085486A2 (en) 2012-11-30 2014-06-05 Waters Technologies Corporation Methods and apparatus for the analysis of vitamin d metabolites
EP2970177A1 (en) 2013-03-15 2016-01-20 Pfizer Inc. Indole compounds that activate ampk
CN107108601B (zh) 2014-08-28 2021-08-20 阿森纽荣股份公司 糖苷酶抑制剂
BR112017026392B1 (pt) * 2015-06-09 2023-12-26 Onconic Therapeutics Inc Composto derivado tricíclico, método para sua preparação e seu uso
US11261183B2 (en) 2016-02-25 2022-03-01 Asceneuron Sa Sulfoximine glycosidase inhibitors
US10696668B2 (en) 2016-02-25 2020-06-30 Asceneuron Sa Acid addition salts of piperazine derivatives
US11612599B2 (en) 2016-02-25 2023-03-28 Asceneuron Sa Glycosidase inhibitors
MX2018010191A (es) 2016-02-25 2019-05-20 Asceneuron S A Inhibidores de glucosidasa.
EP3585783A2 (en) 2016-02-25 2020-01-01 Asceneuron SA Sulfoximine glycosidase inhibitors
EP3672959A1 (en) 2017-08-24 2020-07-01 Asceneuron SA Linear glycosidase inhibitors
EP3672958B1 (en) 2017-08-24 2023-08-02 Asceneuron SA Annulated glycosidase inhibitors
WO2020039029A1 (en) 2018-08-22 2020-02-27 Asceneuron S. A. Spiro compounds as glycosidase inhibitors
US12016852B2 (en) 2018-08-22 2024-06-25 Asceneuron Sa Pyrrolidine glycosidase inhibitors
WO2020039028A1 (en) 2018-08-22 2020-02-27 Asceneuron S. A. Tetrahydro-benzoazepine glycosidase inhibitors
SG11202101651RA (en) 2018-08-22 2021-03-30 Asceneuron S A Succinate and fumarate acid addition salts of piperazine derivatives useful as glycosidase inhibitors
WO2020169804A1 (en) 2019-02-22 2020-08-27 Asceneuron Sa Fused glycosidase inhibitors
EP3999506B1 (en) * 2019-07-19 2025-01-15 Astrazeneca AB Parp1 inhibitors
EP4003358B1 (en) * 2019-07-26 2025-12-31 Health Research, Inc. TREATMENT OF P53 DEFICIENCY CANCERS
US11795158B2 (en) * 2020-06-25 2023-10-24 Astrazeneca Ab Chemical compounds
US20240208969A1 (en) * 2021-04-12 2024-06-27 Impact Therapeutics (Shanghai), Inc. Substituted fused bicyclic compounds as parp inhibitors and the use thereof
EP4326720A4 (en) 2021-04-19 2025-03-19 Xinthera, Inc. Parp1 inhibitors and uses thereof
WO2022222921A1 (zh) * 2021-04-22 2022-10-27 微境生物医药科技(上海)有限公司 含哌嗪结构的parp抑制剂、其制备方法及医药用途
CN116867783A (zh) * 2021-04-23 2023-10-10 成都百裕制药股份有限公司 吡啶衍生物及其在医药上的应用
WO2022222966A1 (zh) * 2021-04-23 2022-10-27 成都百裕制药股份有限公司 一种选择性parp1抑制剂及其应用
WO2022222995A1 (zh) * 2021-04-23 2022-10-27 南京明德新药研发有限公司 吡啶酰胺类化合物
CN115232154A (zh) * 2021-04-23 2022-10-25 上海翰森生物医药科技有限公司 杂环类衍生物抑制剂、其制备方法和应用
MX2023013890A (es) 2021-05-24 2023-12-11 Jiangsu Hengrui Pharmaceuticals Co Ltd Compuesto heterociclico que contiene nitrogeno, metodo de preparacion del mismo y aplicacion del mismo en medicamentos.
CN118119618A (zh) * 2021-09-09 2024-05-31 南京奥利墨斯医药科技有限公司 一种杂芳环类化合物及其应用
WO2023046034A1 (zh) * 2021-09-22 2023-03-30 明慧医药（杭州）有限公司 一种含氮杂环化合物、其制备方法、其中间体及其应用
WO2023046149A1 (zh) * 2021-09-26 2023-03-30 张文燕 喹喔啉类化合物及其医药用途
CN118019740A (zh) * 2021-09-30 2024-05-10 海思科医药集团股份有限公司 杂芳基衍生物parp抑制剂及其用途
EP4410791A4 (en) * 2021-09-30 2025-10-22 Xizang Haisco Pharmaceutical Co Ltd BICYCLIC DERIVATIVE PARP INHIBITOR AND ITS USE
CN118043322A (zh) * 2021-09-30 2024-05-14 西藏海思科制药有限公司 含氮杂环衍生物parp抑制剂及其用途
KR20250145706A (ko) 2021-10-01 2025-10-13 신테라, 인크. 아제티딘 및 피롤리딘 parp1 저해제, 및 이의 용도
AU2022373697A1 (en) * 2021-10-22 2024-05-30 Xizang Haisco Pharmaceutical Co., Ltd. Parp-1 degradation agent and use thereof
MX2024006074A (es) * 2021-11-19 2024-06-28 Kangbaida Sichuan Biotechnology Co Ltd Inhibidor de parp1 selectivo y aplicacion del mismo.
CN118382624A (zh) * 2021-12-17 2024-07-23 凯复(苏州)生物医药有限公司 Parp抑制剂、包含其的药物组合物及其用途
CN118434725B (zh) * 2022-01-20 2026-01-02 微境生物医药科技(上海)有限公司 吡啶酰胺类parp抑制剂、及其制备方法和医药用途
CN120081844A (zh) * 2022-01-21 2025-06-03 新特拉有限公司 Parp1抑制剂及其用途
WO2023146957A1 (en) * 2022-01-27 2023-08-03 Xinthera, Inc. Parp1 inhibitors and uses thereof
JP2025503116A (ja) * 2022-01-28 2025-01-30 シンセラ， インコーポレイテッド Ｐａｒｐ１阻害薬及びその使用
US20250214980A1 (en) 2022-03-14 2025-07-03 Slap Pharmaceuticals Llc Multicyclic compounds
EP4514795A4 (en) * 2022-04-28 2025-12-31 Ningbo Newbay Tech Development Co Ltd COMPOUNDS USED AS PARP1 INHIBITORS
EP4355749B1 (en) 2022-04-28 2025-06-04 Xinthera, Inc. Tricyclic parp1 inhibitors and uses thereof
WO2023207284A1 (en) * 2022-04-28 2023-11-02 Ningbo Newbay Technology Development Co., Ltd Piperazine derivatives as parp1 inhibitiors
AU2023275808A1 (en) * 2022-05-25 2024-12-12 Xizang Haisco Pharmaceutical Co., Ltd. Bicyclic derivative parp inhibitor and use thereof
WO2024041608A1 (zh) * 2022-08-24 2024-02-29 四川海思科制药有限公司 一种杂芳基衍生物parp抑制剂的晶体形式及其用途
WO2024041605A1 (zh) * 2022-08-24 2024-02-29 四川海思科制药有限公司 一种杂芳基衍生物parp抑制剂药学上可接受的盐及其用途
CN117658983A (zh) * 2022-09-01 2024-03-08 浙江文达医药科技有限公司 选择性parp1抑制剂
WO2024083201A1 (zh) * 2022-10-20 2024-04-25 成都赜灵生物医药科技有限公司 并杂环类化合物及其用途
WO2024083218A1 (zh) * 2022-10-20 2024-04-25 成都赜灵生物医药科技有限公司 取代四氢吡啶类化合物及其用途
TW202421139A (zh) 2022-11-23 2024-06-01 大陸商江蘇恆瑞醫藥股份有限公司 一種含氮雜環類化合物的可藥用鹽、晶型及製備方法
AU2023412594A1 (en) * 2022-12-23 2025-07-10 Zhejiang Yangli Pharmaceutical Technology Co., Ltd. Parp1 inhibitors
CN117903159A (zh) * 2022-12-30 2024-04-19 成都硕德药业有限公司 一种内酰胺类衍生物、其制备方法及用途
WO2025101892A1 (en) * 2023-11-10 2025-05-15 Astellas Engineered Small Molecules US, Incorporated Poly-adp ribose polymerase (parp) inhibitors and uses thereof
CN120040415A (zh) * 2023-11-24 2025-05-27 中国药科大学 一种含喹啉酮骨架的化合物及其应用
WO2025168048A1 (zh) * 2024-02-08 2025-08-14 上海璎黎药业有限公司 一种三键结构化合物、其药物组合物及其应用

Family Cites Families (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB732581A (en) 1952-01-18 1955-06-29 Ciba Ltd Manufacture of hydrazine compounds
DE1006423B (de) 1952-01-18 1957-04-18 Ciba Geigy Verfahren zur Herstellung von Hydrazinophthalazinen
US3274194A (en) 1963-03-29 1966-09-20 Miles Lab Quinazolinedione derivatives
GB1062357A (en) 1965-03-23 1967-03-22 Pfizer & Co C Quinazolone derivatives
GB1293565A (en) 1969-05-03 1972-10-18 Aspro Nicholas Ltd Aminophthalazines and pharmaceutical compositions thereof
US3919425A (en) 1971-04-09 1975-11-11 Miles Lab Method of producing vasodilation using certain 3-substituted-quinazoline derivatives
BE792206A (enExample) 1971-12-02 1973-06-01 Byk Gulden Lomberg Chem Fab
FR2436781A1 (fr) 1978-09-19 1980-04-18 Berri Balzac Derives d'amino-3 (1h,3h) quinazolinedione-2,4, leur procede de preparation et leurs applications en therapeutique
US4335127A (en) 1979-01-08 1982-06-15 Janssen Pharmaceutica, N.V. Piperidinylalkyl quinazoline compounds, composition and method of use
JPS5976082A (ja) 1982-10-23 1984-04-28 Kyowa Hakko Kogyo Co Ltd 新規なピペリジン誘導体
JPS60120872A (ja) 1983-12-01 1985-06-28 Kyowa Hakko Kogyo Co Ltd 新規なヘテロ環状化合物及び強心剤
PL147465B1 (en) 1984-03-26 1989-06-30 Janssen Pharmaceutica Nv Method of obtaining novel pyridazionoamine compounds
US5001125A (en) 1984-03-26 1991-03-19 Janssen Pharmaceutica N.V. Anti-virally active pyridazinamines
DK623586A (da) 1985-12-27 1987-06-28 Eisai Co Ltd Piperidinderivater eller salte deraf og farmaceutiske kompositioner indeholdende forbindelserne
US5231184A (en) 1987-11-23 1993-07-27 Janssen Pharmaceutica N.V. Pridazinamine derivatives
US5177075A (en) 1988-08-19 1993-01-05 Warner-Lambert Company Substituted dihydroisoquinolinones and related compounds as potentiators of the lethal effects of radiation and certain chemotherapeutic agents; selected compounds, analogs and process
CA2002864C (en) 1988-11-29 1999-11-16 Eddy J. E. Freyne (1h-azol-1-ylmethyl) substituted quinoline, quinazoline or quinoxaline derivatives
GB8827822D0 (en) 1988-11-29 1988-12-29 Janssen Pharmaceutica Nv (1h-azol-1-ylmethyl)substituted quinoline derivatives
US5374637A (en) 1989-03-22 1994-12-20 Janssen Pharmaceutica N.V. N-(3-hydroxy-4-piperidinyl)(dihydrobenzofuran, dihydro-2H-benzopyran or dihydrobenzodioxin)carboxamide derivatives
EP0391462A1 (en) 1989-04-05 1990-10-10 Janssen Pharmaceutica N.V. Synergistic compositions containing ketanserin
US5160727A (en) 1990-02-13 1992-11-03 Warner-Lambert Company Tumor cell sensitization method using quinazolinedione derivatives
IE913473A1 (en) 1990-10-15 1992-04-22 Fujisawa Pharmaceutical Co Quinazoline derivatives and their preparation
KR100259107B1 (ko) 1992-04-23 2000-07-01 슈테펜 엘. 네스비트 세로토닌 5ht₂길항제로서의 4-이미도메틸-1-[2'-페닐-2'-옥소에틸]피페리딘, 이의 제조방법 및 이를 포함하는 약제학적 조성물
TW294595B (enExample) 1992-11-20 1997-01-01 Janssen Pharmaceutica Nv
US5624926A (en) 1993-02-18 1997-04-29 Kyowa Hakko Kogyo Co., Ltd. Piperidinyl-dioxoquinazolines as adenosine reuptake inhibitors
GB9404485D0 (en) 1994-03-09 1994-04-20 Cancer Res Campaign Tech Benzamide analogues
TW445263B (en) 1996-02-29 2001-07-11 Janssen Pharmaceutica Nv Novel esters of 1,4-disubstituted piperidine derivatives
JPH107572A (ja) 1996-06-17 1998-01-13 Sumitomo Pharmaceut Co Ltd 腫瘍壊死因子産生阻害剤
ATE266673T1 (de) 1996-09-10 2004-05-15 Boehringer Ingelheim Pharma Abgewandelte aminosäuren, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
WO1998054135A1 (en) 1997-05-30 1998-12-03 Meiji Seika Kaisha, Ltd. Nitrogenous heterocyclic compounds and hyperlipemia remedy containing the same
JPH10330377A (ja) 1997-06-02 1998-12-15 Kyowa Hakko Kogyo Co Ltd ピペリジン誘導体
US6635642B1 (en) 1997-09-03 2003-10-21 Guilford Pharmaceuticals Inc. PARP inhibitors, pharmaceutical compositions comprising same, and methods of using same
US20020022636A1 (en) * 1997-09-03 2002-02-21 Jia-He Li Oxo-substituted compounds, process of making, and compositions and methods for inhibiting parp activity
CA2302453A1 (en) 1997-09-16 1999-03-25 Atsuhiro Inaba Nitrogenous fused-ring compounds, process for the preparation of the same, and drugs
US6133277A (en) 1997-12-05 2000-10-17 Janssen Pharmaceutica N.V. (Benzodioxan, benzofuran or benzopyran) derivatives having fundic relaxation properties
JP2000191659A (ja) 1999-01-04 2000-07-11 Sumitomo Pharmaceut Co Ltd 腫瘍壊死因子産生阻害剤
US7265115B2 (en) 1999-01-29 2007-09-04 Abbott Laboratories Diazabicyclic CNS active agents
BR0007664A (pt) 1999-01-29 2002-05-07 Abbott Lab Derivados diazabicìclicos como ligantes receptores de acetilcolina nicotìnicos
US6566372B1 (en) 1999-08-27 2003-05-20 Ligand Pharmaceuticals Incorporated Bicyclic androgen and progesterone receptor modulator compounds and methods
CN1703403A (zh) 2000-10-02 2005-11-30 詹森药业有限公司 趋代谢的谷氨酸盐受体拮抗剂
ITMI20002358A1 (it) 2000-10-31 2002-05-01 Flavio Moroni Derivati di tieno ,2, 3-c|isochinolin-3-one come inibitori della poli(a dp-ribosio)polimerasi
AUPR201600A0 (en) 2000-12-11 2001-01-11 Fujisawa Pharmaceutical Co., Ltd. Quinazolinone derivative
JP2002284699A (ja) 2001-03-28 2002-10-03 Sumitomo Pharmaceut Co Ltd 視細胞変性疾患治療剤
EP1396488A1 (en) 2001-05-23 2004-03-10 Mitsubishi Pharma Corporation Fused heterocyclic compound and medicinal use thereof
US6924284B2 (en) 2001-08-15 2005-08-02 Icos Corporation PARP inhibitors
JP2005511581A (ja) 2001-11-07 2005-04-28 メルク　エンド　カムパニー　インコーポレーテッド 有糸分裂キネシン阻害剤
AUPR975601A0 (en) 2001-12-24 2002-01-31 Fujisawa Pharmaceutical Co., Ltd. Quinazolinone derivatives
US6822097B1 (en) * 2002-02-07 2004-11-23 Amgen, Inc. Compounds and methods of uses
AUPS137402A0 (en) 2002-03-26 2002-05-09 Fujisawa Pharmaceutical Co., Ltd. Novel tricyclic compounds
MXPA04009435A (es) 2002-03-29 2005-01-25 Janssen Pharmaceutica Nv Derivados de quinolina y quinolinona radiomarcados y su uso como ligandos de receptor de glutamato metabotropico.
US7119111B2 (en) 2002-05-29 2006-10-10 Amgen, Inc. 2-oxo-1,3,4-trihydroquinazolinyl derivatives and methods of use
WO2004048339A1 (ja) * 2002-11-22 2004-06-10 Mitsubishi Pharma Corporation イソキノリン化合物及びその医薬用途
US20050075364A1 (en) 2003-07-01 2005-04-07 Kap-Sun Yeung Indole, azaindole and related heterocyclic N-substituted piperazine derivatives
MXPA06005687A (es) 2003-11-20 2006-08-17 Janssen Pharmaceutica Nv 2-quinolinonas y 2-quinoxalinonas sustituidas con 6-alquenilo y 6-fenilalquilo como inhibidores de la poli(adenosin fosfato-ribosa)polimerasa.
JP4864718B2 (ja) * 2003-11-20 2012-02-01 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ポリ（ａｄｐ−リボース）ポリメラーゼ阻害剤としての６−アルケニルおよび６−フェニルアルキル置換２−キノリノンおよび２−キノキサリノン
SG150534A1 (en) * 2003-11-20 2009-03-30 Janssen Pharmaceutica Nv 7-phenylalkyl substituted 2-quinolinones and 2-quinoxalinones as poly(adp- ribose) polymerase inhibitors
KR101206843B1 (ko) 2003-12-03 2012-11-30 와이엠 바이오사이언시즈 오스트레일리아 피티와이 엘티디 튜불린 저해제
BRPI0416532A (pt) 2003-12-05 2007-01-09 Janssen Pharmaceutica Nv 2-quinolinonas e 2-quinoxalinonas substituìdas por 6 como inibidores da poli(adp-ribose) polimerase
KR101149031B1 (ko) * 2003-12-10 2012-05-29 얀센 파마슈티카 엔.브이. 폴리(ａｄｐ-리보스)폴리머라제 저해제로서의 치환된6-사이클로헥실알킬 치환된 2-퀴놀리논 및 2-퀴녹살리논
PE20060285A1 (es) 2004-03-30 2006-05-08 Aventis Pharma Inc Piridonas sustituidas como inhibidores de pol(adp-ribosa)-polimerasa (parp)
CA2568622C (en) 2004-06-01 2016-01-26 University Of Virginia Patent Foundation Dual small molecule inhibitors of cancer and angiogenesis
UA88012C2 (uk) 2004-06-30 2009-09-10 Янссен Фармацевтика Н.В. Похідні хіназоліндіону як інгібітори parp
ES2563954T3 (es) 2004-06-30 2016-03-16 Janssen Pharmaceutica Nv Derivados de ftalazina como inhibidores de PARP
MXPA06014933A (es) 2004-06-30 2007-02-28 Janssen Pharmaceutica Nv Derivados de 2-alquil quinazolinona sustituidos como inhibidores de poli(adp-ribosa) polimerasa-1.
KR101364762B1 (ko) 2005-02-17 2014-02-17 신타 파마슈티칼스 코프. 증식성 장애의 치료를 위한 화합물
JP5075624B2 (ja) 2005-04-28 2012-11-21 田辺三菱製薬株式会社 シアノピリジン誘導体及びその医薬としての用途
KR20080039508A (ko) 2005-08-24 2008-05-07 이노텍 파마슈티컬스 코포레이션 인데노이소퀴놀리논 유사체 및 이의 사용 방법
WO2007087684A1 (en) 2006-02-03 2007-08-09 Bionomics Limited Substituted benzofurans, benzothiophenes, benzoselenophenes and indoles and their use as tubulin polymerisation inhibitors
CA2641776C (en) 2006-02-15 2014-04-08 Abbott Laboratories Pyrazoloquinolones are potent parp inhibitors
US8466150B2 (en) 2006-12-28 2013-06-18 Abbott Laboratories Inhibitors of poly(ADP-ribose)polymerase
AU2008223793B2 (en) 2007-03-08 2012-08-23 Janssen Pharmaceutica Nv Quinolinone derivatives as PARP and TANK inhibitors
EP2170866B1 (en) 2007-06-25 2014-08-13 Amgen Inc. Phthalazine compounds, compositions and methods of use

Also Published As

Publication number Publication date
JP2011500758A (ja) 2011-01-06
ES2448870T3 (es) 2014-03-17
US8404713B2 (en) 2013-03-26
WO2009053373A1 (en) 2009-04-30
US20100222348A1 (en) 2010-09-02
EP2215075A1 (en) 2010-08-11
JP5525447B2 (ja) 2014-06-18
EP2215075B1 (en) 2013-12-11

Similar Documents

Publication Publication Date Title
PL2215075T3 (pl) Pochodne chinolinonu jako inhibitory PARP
IL205142A0 (en) Pyridazinone derivatives as parp inhibitors
IL208103A0 (en) Quinoline derivatives as axl kinase inhibitors
IL193265A0 (en) Quinoline derivatives
IL202018A0 (en) Quinoline derivatives as pi3 kinase inhibitors
EP2194044A4 (en) QUINOLONE DERIVATIVE
IL200656A0 (en) Quinoline derivatives as fungicides
ZA201005166B (en) 2-benzylpyridazinone derivatives as met kinase inhibitors
IL208203A0 (en) Heterocyclic derivatives
IL193272A0 (en) Pyrazoloquinolones are potent parp inhibitors
IL212755A0 (en) Pyrazinopyrazines and derivatives as kinase inhibitors
IL212842A0 (en) Azaindole derivatives as kinase inhibitors
ZA201007317B (en) Tertiary amine derivatives as phosphodiesterase-4 inhibitors
ZA201005382B (en) Substituted heteroarylamide diazepinopyrimidone derivatives
IL196000A0 (en) 2-arylindole derivatives as npges-i inhibitors
IL208626A0 (en) Imidazolidinone derivatives as 11b-hsd1 inhibitors
IL207191A0 (en) Substituted heteroaylamide oxazepyrimidone derivatives
ZA200906423B (en) Pyrazolone derivatives as PDE4 inhibitors
IL206949A0 (en) 2-aminoquinoline derivatives
EP2344472A4 (en) ISOCHINOLINONDERIVATE
GB0714941D0 (en) Inhibitors
ZA200806877B (en) Quinoline Derivatives
GB0713152D0 (en) Phosphodlesterase inhibitors
HK1158642A (en) Isoquinolinone derivatives
GB0621107D0 (en) Inhibitors of phosphodiesterase-4